RT Journal Article
SR Electronic
T1 The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.27.24314479
DO 10.1101/2024.09.27.24314479
A1 Vanheer, Leen N
A1 Ramjith, Jordache
A1 Mahamar, Almahamoudou
A1 Smit, Merel J
A1 Lanke, Kjerstin
A1 Roh, Michelle E
A1 Sanogo, Koualy
A1 Sinaba, Youssouf
A1 Niambele, Sidi M.
A1 Diallo, Makonon
A1 Maguiraga, Seydina O
A1 Keita, Sekouba
A1 Samake, Siaka
A1 PharmD, Ahamadou Youssouf
A1 Diawara, Halimatou
A1 Traore, Sekou F.
A1 Gosling, Roly
A1 Brown, Joelle M
A1 Drakeley, Chris
A1 Dicko, Alassane
A1 Stone, Will
A1 Bousema, Teun
YR 2024
UL http://medrxiv.org/content/early/2024/09/29/2024.09.27.24314479.abstract
AB Background Interrupting human-to-mosquito transmission is important for malaria elimination strategies as it can reduce infection burden in communities and slow the spread of drug resistance. Antimalarial medications differ in their efficacy in clearing the transmission stages of Plasmodium falciparum (gametocytes) and in preventing mosquito infection. Here we present a combined analysis of six trials conducted at the same study site with highly consistent methodologies that allows for a direct comparison of the gametocytocidal and transmission-blocking activities of fifteen different antimalarial regimens or dosing schedules.Methods and findings Between January 2013 and January 2023, six clinical trials with transmission endpoints were conducted at the Clinical Research Centre of the Malaria Research and Training Centre of the University of Bamako in Mali. These trials tested Artemisinin-Combination Therapies (ACTs), non-ACT regimens and combinations with 8-aminoquinolines. Participants were males and non-pregnant females, between 5-50 years of age, who presented with P. falciparum mono-infection and gametocyte carriage by microscopy. Blood samples were taken before and after treatment for thick film microscopy, infectivity assessments by mosquito feeding assays and molecular quantification of gametocytes. Mixed-effects generalized linear models were fit with individual-specific random effects and fixed effects for time points, treatment groups and their interaction. Models quantified changes in mosquito infection rates and gametocyte densities within treatment arms over time and between treatments. In a pooled analysis of 422 participants, we observed substantial differences between ACTs in gametocytocidal and transmission-blocking activities, with artemether-lumefantrine (AL) being significantly more potent at reducing mosquito infection rates within 48 hours than dihydroartemisinin-piperaquine (DHA-PPQ), artesunate-amodiaquine (AS-AQ) and pyronaridine-artesunate (PY-AS) (p<0.0001). The addition of single low dose primaquine (SLD PQ) accelerated gametocyte clearance and led to a significantly greater reduction in mosquito infection rate within 48-hours of treatment for each ACT, while an SLD of the 8-aminoaquinoline tafenoquine (TQ) showed a delayed but effective response compared to SLD primaquine. Finally, our findings confirmed considerably higher post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) compared to most ACTs, with a significantly lower relative reduction in mosquito infection rate at day 7 compared to DHA-PPQ, AS-AQ, and AL (p<0.0001). Therefore, adding an SLD PQ to SP-AQ may be beneficial to block malaria transmission in community treatment campaigns.Conclusions We found marked differences among ACTs and single low-dose 8-aminoquinoline drugs in their ability and speed to block transmission. The findings from this analysis can support treatment policy decisions for malaria elimination and be integrated into mathematical models to improve the accuracy of predictions regarding community transmission and the spread of drug resistance under varying treatment guidelines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe original studies were registered with ClinicalTrials.gov (NCT01743820, NCT02831023, NCT04049916, NCT04609098, NCT05081089 and NCT05550909).Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals for the individual studies were obtained from the Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry of the University of Science, Techniques, and Technologies of Bamako (Bamako, Mali). In addition, the studies were approved by the Committee on Human Research at the University of California (San Francisco, CA, USA), and/or the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (London, UK).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesACTartemisinin-based combination therapyALArtemether-lumefantrineAL-AQArtemether-lumefantrine-amodiaquineAQAmodiaquineAS-AQArtesunate-AmodiaquineDHA-PPQDihydroartemisinin-PiperaquineG6PDglucose-6-phosphate dehydrogenasePY-ASPyronaridine-ArtesunatePQPrimaquineSLDSingle low-doseRT-qPCRreverse-transcriptase quantitative PCRSP-AQSulfadoxine-pyrimethamine plus AmodiaquineTACTTriple artemisinin-based combination therapyTQTafenoquineWHOWorld Health Organisation